Adults Now Outnumber Children Living With Congenital Heart Disease
Hospiten highlights that advances in medical care have led to more adults than children now living with congenital heart disease, creating new challenges for lifelong specialized support as World Congenital Heart Disease Day approaches.
With World Congenital Heart Disease Day approaching on February 14, the Hospiten healthcare network is highlighting a significant change in how these conditions are managed: there are now more adults than children living with congenital heart disease. This shift brings new challenges for healthcare and social support. Hospiten stresses that diagnosing these conditions before birth is a crucial tool for early detection and planning treatment.
Congenital heart disease refers to problems with the heart or major blood vessels that are present from birth. It is the most common birth defect, affecting about 8 out of every 1,000 babies born alive. These issues develop during the first eight weeks of pregnancy, when the heart structures are forming. They can range from mild defects that get better on their own to complex problems that need surgery soon after birth.
Until the mid-20th century, many children with these heart conditions did not survive. However, advances in prenatal diagnosis, newborn care, heart surgery, and specialized follow-up have completely changed their outlook. Now, most affected individuals in developed countries live into adulthood. Hospiten specialists say this milestone is not just about survival, but also about quality of life and being part of society. It means these individuals need ongoing, specialized medical monitoring throughout their lives.
Care for these patients extends beyond the individual to their families, creating emotional, psychological, educational, and professional challenges. These require a complete and coordinated approach. In this context, the work of patient and family associations is vital, not only as a support network but also for spreading information, advocating for rights, and promoting research.
Research into congenital heart disease is progressing rapidly. Diagnosing conditions before birth is becoming more precise, making it easier to plan treatments even before a baby is born. Genetics and molecular biology offer the promise of more personalized medicine, while new technologies like minimally invasive treatments, 3D printing for surgical planning, and artificial intelligence applied to heart imaging are opening new avenues for better outcomes. Nevertheless, experts say the main challenge is not just technical, but human and organizational: ensuring that all individuals with these conditions, regardless of where they were born or their age, have access to specialized, fair, and continuous care.
In this context, Hospiten, an international healthcare network, is using this occasion to raise public awareness. With over 55 years of experience, Hospiten operates 20 private hospitals and medical centers across Spain, the Dominican Republic, Mexico, Jamaica, and Panama, along with 175 outpatient centers under its Clinic Assist brand. Founded by Dr. Pedro Luis Cobiella, the organization treats over three million patients annually and employs more than 5,000 professionals. Hospiten is further expanding its commitment by building a university general hospital in Boadilla del Monte, Madrid, expected to open in 2026. Additionally, Hospiten is the Spanish partner of the MD Anderson Cancer Center of Houston, a partnership that has lasted over two decades in Spain, featuring a Phase I Clinical Trials Unit and advanced equipment for cancer diagnosis and treatment.